Teens who avidly seek new and intense sensations are more likely to start using substances, but are not more likely to use them regularly within the next 3 years unless they also are prone to devalue distant consequences and act impulsively.
Treatment that combines use of Bp/Nx and memantine may enable young adults addicted to opioids establish lasting abstinence after a relatively brief course of medication-assisted therapy, a pilot trial suggests.
Giving mice a modified version of a naturally occurring gene blocks cocaine’s stimulant effects without affecting the animals’ physiological or metabolic health. The new evidence advances the proposed therapy a step closer to readiness for testing in people.
In the first long-term follow-up of patients treated with buprenorphine/naloxone for addiction to opioid pain relievers, half reported that they were abstinent from the drugs 18 months after starting the therapy.